LV reverse remodeling (LVRR) (Hoshikawa et al., 2011; Merlo et al., 2011) . LVRR is recognized as a surrogate marker of good prognosis and has been used as a guide for the design of appropriate therapeutic strategy. Echocardiography is the standard tool used to evaluate the presence of LVRR, but has problems related to interobserver variability and inappropriate testing due to technical irregularities (Bhattacharyya & Lloyd, 2015) . A more convenient and reproducible tool is desirable especially for general practitioners.
Electrocardiography (ECG) is simple and widely used to provide information on cardiac function status such as LV hypertrophy.
Sokolow-Lyon voltage index correlates with LV mass and changes with geometric remodeling in patients with hypertension, and is widely used as an ECG diagnostic index for LV hypertrophy (LVH) (Sokolow & Lyon, 1949) . Indeed ECG identification of LVH is recommended by all guidelines on hypertension for routine risk prediction. However, the Sokolow-Lyon index is less sensitive than echocardiography for the diagnosis of LVH (Reichek & Devereux, 1981) . The low sensitivity of the Sokolow-Lyon index is due to the effects of cardiogenic factors (e.g., amount of electromotive force and heart geometry), and noncardiogenic factors (e.g., pericardial and pleural effusion, distance from heart to body surface) on ECG voltage (Bang, Devereux, & Okin, 2014; Okin, Roman, Devereux, & Kligfield, 1996) . However, the SokolowLyon index is suitable for evaluation and monitoring serial changes in cardiac geometry within individuals as long as these conditions are stable (Castini, Vitolo, Ornaghi, & Gentile, 1996; Wachtell et al., 2002) .
Since LVH is the hallmark of chronic pressure or volume overload of the LV and correlates with risk of cardiovascular morbidity and mortality, ECG-LVH is considered a poor prognostic marker of cardiovascular morbidity and mortality irrespective of etiology (Hawkins et al., 2007; Kannel, 1983; Kannel, Gordon, & Offutt, 1969) . On the other hand, low Sokolow-Lyon voltage is associated with favorable prognosis and correlates with decrease in echocardiographic LV mass in hypertensive patients (Levy, Salomon, D'Agostino, Belanger, & Kannel, 1994; Okin, 2009; Verdecchia et al., 2009) . It has also been reported that a decrease in LV mass in IDCM patients is also associated with LVRR (Palazzuoli et al., 2002) , but there is no information on whether the Sokolow-Lyon voltage (SV 1 +RV 5/6 ) is affected by geometrical changes typically seen in IDCM patients. The aim of the present study was to determine the association of serial changes in Sokolow-Lyon (SV 1 +RV 5/6 ) voltage with LVRR and prognosis in IDCM patients under tailored medical therapy.
| METHODS

| Study population
The present retrospective study included 68 consecutive IDCM patients diagnosed with New York Heart Association (NYHA) functional class I to III admitted to Nagoya University Hospital between July 2008 and January 2014.
DCM was defined as the presence of both dilated LVDd (>55 mm) and reduced LV ejection fraction (LVEF) (≤50%), as determined by echocardiography (Palazzuoli et al., 2002) in the absence of specific pathological changes of other cardiomyopathies (e.g., disarray, vacuolization, thickening of vascular endothelial cells, granuloma, infiltration of inflammatory cells) as confirmed by endomyocardial biopsy. Patients with evidence of previous coronary artery disease, primary valvular disease, severe arterial hypertension, histological myocarditis, secondary cardiac muscle disease, bundle branch block, implanted pacemaker or cardiac resynchronization therapy, significant pericardial and pleural effusion were excluded.
The study protocol was approved by the Human Ethics Review Board of Nagoya University School of Medicine (#359) and a signed consent form was obtained from each subject.
| Study protocol
At baseline, each patient underwent 12-lead ECG, M-mode and bidimensional echocardiography, color Doppler, right and left catheterization with coronary angiography, laboratory analysis and endomyocardial biopsy. Furthermore, ECG and echocardiography were repeated at 12 months follow-up when the patient was under optimum medical therapy.
| Electrocardiographic evaluation
The Electrocardiograph FCP-7541 (Fukuda Denshi Co., Tokyo, Japan), which has been approved by the Japan Ministry of Health, Labour and Welfare, was used to record ECG. We defined as the QRS voltage as the maximum sum of voltage of S wave in V 1 and R wave in V 5 or V 6 according to the Sokolow-Lyon index (Sokolow & Lyon, 1949) . QRS voltage, QRS duration, QTc duration were computed. The absolute (∆) and percent change (∆%) of QRS voltage during the 12-month period were evaluated statistically.
| Echocardiographic evaluation
Two-dimensional and Doppler echocardiography were performed in all patients according to the guidelines of the American Society of Echocardiography using Vivid 7 system (GE Healthcare, Milwaukee, WI, USA) (Palazzuoli et al., 2002) . The LVDd, interventricular septal wall thickness (IVST), and posterior wall thickness (PWT) were measured using the M-mode, while LVEF was calculated using the biplane Simpson's method. The LV mass (LVM) was normalized for body surface area (BSA) as LV mass index (LVMI).
| Evaluation of LVRR and clinical events
LVRR was defined as increase of ≥10% in LVEF and decrease of ≥10% in LVDd at 12-month follow-up (Palazzuoli et al., 2002) . The composite clinical events of cardiovascular death, hospitalization for worsening HF, and fatal arrhythmia were monitored at the end of the 12-month follow-up period.
| Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range), and categorical variables 
| RESULTS
| Baseline characteristics of patients
Of the enrolled 68 patients, LVRR was identified in 30 (44.1%). The median follow-up period was 3.9 (2.3-4.9) years. As shown in Table 1 , more than 90% of the patients were classified as NYHA functional class I or II, and most of the patients had compensated HF at baseline. Plasma B-type natriuretic peptide (BNP) levels were not strikingly elevated, and the hemodynamic data were within the normal limits in the LVRR and non-LVRR groups. The LVRR group included more hypertensive patients, but all other laboratory data, with the exception of plasma sodium and estimated glomerular filtration rate (eGFR), were comparable between the two groups. The difference in plasma sodium level was significant, but subtle. eGFR was significantly lower in the LVRR group than the non-LVRR group. The hemodynamic data, with the exception of mean right atrial pressure (RAP), were comparable, and the mean RAP was within the normal range in both groups.
Approximately half of the patients were being treated with β-blockers together with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-II receptor blockers (ARB) and mineralocorticoid receptor antagonist (MRA) at baseline. Fewer patients received β-blockers, but more were being treated with MRA and diuretics, in the LVRR group, compared with the non-LVRR group. The percentages of patients being treated and types of medications at 12-month follow-up were comparable between the two groups. Table 2 shows comparison of ECG and echocardiographic parameters between the LVRR and non-LVRR groups at baseline and 12-month follow-up. All ECG parameters listed in Table 2 were comparable between the two groups at both baseline and 12-month follow-up.
| ECG and echocardiographic parameters at baseline and 12 months follow-up
The echocardiographic parameters, with the exception of LV posterior wall thickness (PWT), were also comparable at baseline between the two groups. PWT was significantly larger in the LVRR group at baseline (9.5 ± 1.8 mm vs. 8.3 ± 1.5 mm; p = .004). Meanwhile, a greater improvement in LVEF and more significant reduction in LVDd and LVMI were observed in the LVRR group at 12-month follow-up (LVEF: 54.8 ± 7.3 vs. 39.0 ± 11.6%; p < .001; LVDd: 52.3 ± 5.9 vs.
62.0 ± 7.1 mm; p < .001; LVMI: 127.1 ± 26.1 vs. 158.6 ± 40.8 g/m 2 , p < .001 respectively). The wall thickness was comparable between the two groups at 12-month follow-up. Table 3 shows the serial changes in ECG and echocardiographic parameters of both groups. After optimum medical treatment, QRS voltage in the LVRR group was markedly reduced after 12-month follow-up (4.24 ± 1.49 vs. 2.93 ± 1.00 mV, respectively; p < .001), but that of the non-LVRR group was comparable. QRS and QTc durations did not change in both groups at 12-month follow-up. The echocardiographic data showed that medical therapy significantly increased LVFE, and decreased LVDd and LVMI in the LVRR group at the 12-month follow-up, and that wall thickness was comparable between the two groups. On the other hand, treatment neither reduced LVDd nor LVMI despite significant improvement in LVEF in the non-LVRR group.
| Rate of change in ECG and echocardiographic parameters
In the next step, we analyzed the absolute difference and rate of changes in ECG and echocardiographic parameters in the entire group, LVRR group and non-LVRR group (Table 4) . For ECG parameters, the absolute values of decrease and rate of decrease in QRS amplitude (∆QRS voltage and ∆%QRS voltage, respectively) , and shortening of QRS and QTc duration (∆QRS duration and ∆QTc duration) were significantly larger in the LVRR group than the non-LVRR group. For echocardiographic parameters, the increase in the rate of LVEF (∆%LVEF) and the decreases in the rates of LVDd and LVMI (∆%LVDd and ∆%LVMI) were significantly larger in the LVRR group, although the change in wall thickness was comparable between the two groups. We also used Kaplan-Meier analysis to assess the utility of ∆%QRS voltage for the assessment of prognosis (association of ∆%QRS voltage with composite end-points). Among 68 patients, 13 experienced composite end-points [cardiac death, n = 0, hospitalization for worsening HF, n = 11, and fatal arrhythmia (n = 2) during 3.9 (2.3 to 4.9) years after 12-months follow-up. Kaplan-Meier curves showed significantly higher event-free survival rates in patients who sowed ∆QRS voltage of ≤ −14.7% (p = .026, Figure 3 ). Data are mean±SD, n (%) or median (interquartile range). LVRR, left ventricular reverse remodeling; BSA, body surface area; BMI, body mass index; NYHA, New York Heart Association; SBP, systolic blood pressure; HF, heart failure; BNP, B-type natriuretic peptide; eGFR estimated glomerular filtration rate; PAWP, pulmonary artery wedge pressure; PAP pulmonary artery pressure; RAP right atrial pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRAs, mineralocorticoid receptor antagonists. 31.6 ± 6.7
| Relationship between changes in ECG and echocardiographic parameters
| ∆%QRS voltage ROC analysis for detection of LVRR
T A B L E 1 Baseline characteristics
T A B L E 2 Serial evaluation of electrocardiographic and echocardiographic parameters
54.8 ± 7.3 <.001
32.8 ± 9.2 39.0 ± 11.6
.012
LVDd (mm) 64.7 ± 5.9
57.7 ± 8.2
<.001
65.2 ± 6.0 52.3 ± 5.9
<.001
64.2 ± 5.9
62.0 ± 7.1
.152
IVSTd (mm) 8.7 ± 1.5
8.8 ± 1.4
.599
9.0 ± 1.4
9.1 ± 1.4
.796
8.5 ± 1.6
8.6 ± 1.4
.649
PWTd (mm) 8.8 ± 1.7
9.1 ± 1.8
.342
9.5 ± 1.8
9.4 ± 1.9
.884
8.3 ± 1.5
8.8 ± 1.7
.240
171.9 ± 43.7
144.7 ± 38.3
182.2 ± 37.5
127.1 ± 26.1
163.8 ± 46.9
158.6 ± 40.8
.604
Data are mean ± SD.
| DISCUSSION
The present study showed two novel findings regarding the relationship between serial changes in the Sokolow-Lyon voltage and clinical course in patients with compensated IDCM during tailored medical therapy (Table 1) . First, the ∆%QRS voltage of the Sokolow-Lyon index correlated significantly with Δ%LVEF, ∆%LVDd and ∆%LVMI measured by echocardiography, and the highest correlation was that with ∆%LVDd ( Figure 1) . Second, ∆%QRS voltage less than −14.7%
at 12-month follow-up was associated with the prevalence of LVRR (Figure 2 ) and lower risk of cardiovascular morbidity and mortality in IDCM patients (Figure 3 ).
The Sokolow-Lyon voltage is recognized as a surrogate marker of LVH (Sokolow & Lyon, 1949) , but there is a discrepancy between ECG findings and image studies such as echocardiography and magnetic resonance imaging (Okin et al., 1996; Pewsner et al., 2007; Reichek & Devereux, 1981; Romhilt et al., 1969; Truong et al., 2010) . Since the voltage values are affected and altered by various non-cardiac factors, such as age, gender, distance from the heart to the recording electrodes, chest-wall thickness, edema, pericardial and pleural effusion (Kannel et al., 1969) , these factors were carefully excluded or compensated for in this study. There was the inequality of the medical therapy, including β-blockers, mineralocorticoid-receptor antagonists and diuretics, between the LVRR and non-LVRR groups at the baseline. We considered that this would hardly affect the Sokolow-Lyon index because the hemodynamic indices, such as systemic blood pressure and pulmonary artery wedge pressure, were comparable. Previous studies reported that electrocardiographic diagnosis of LVH is a strong predictor of mortality in patients with mild to moderate HF (Kearney et al., 2002 ), but we found no difference in various ECG parameters between the LVRR and non-LVRR groups at both the baseline and 12-month follow-up (Table 2) . Decrease in Changes in echocardiographic data Δ%LVEF (%) 13.7 ± 13.7 23.1 ± 9.7 6.2 ± 11.7 <.001
ΔLVDd (mm) −6.9 ± 7.4 −12.6 ± 5.0 −2.4 ± 5.7 <.001
Δ%LVDd (%) −10.5 ± 11.4 −19.6 ± 7.6 −3.3 ± 8.3 <.001
ΔIVST ( Data are mean ± SD or median (interquartile range), Δ: changes in absolute value, Δ%: percent change.
Sokolow-Lyon voltage is recognized as evidence for decline in LVMI and LV diameter in hypertensive patients and healthy subjects, respectively (Castini et al., 1996; Okin et al., 2004) , and a surrogate marker for cardiac function and incidence of cardiovascular events in hypertensive patients (Ang & Lang, 2008 (Aronson, 1980; Sokolow & Lyon, 1949; Uhley, 1961) . In the present study, the ∆%QRS voltage was associated with the echocardiographic Δ%LVEF, ∆%LVDd, and ∆%LVMI but not with wall thickness (Figure 1 ). Since our patients were well compensated to show preserved and unchanged LV wall thickness during the observation period (Tables 1-3) , we expected to find no correlation between serial changes in LV wall thickness and ∆%QRS voltage. However, we found larger values in ∆QRS voltage and ∆%QRS voltage in the LVRR group (Table 4 ) and strong association of ∆%QRS voltage with decrease in LVDD (Figure 1 ). In this regard, the physiological study of Castini et al. (Castini et al., 1996) showed that decrease in LVDD induced by reduction of venous return was concordant with decrease in QRS voltage in healthy subjects. In the present study, ∆%QRS voltage reflected altered LV geometry after the tailored therapy. Since significant decreases in ∆QRS and ∆QTc durations were noted in LVRR patients (Table 4) Our study has limitations. The first limitation is the retrospective design and small study in a single center because this study included a highly specific and homogeneous population: all patients were IDCM and almost all patients were classified as NYHA functional class I or II. Second, we excluded the cases which did not match the criteria suitable for ECG observation. We would suggest that further studies be conducted in larger populations in order to determine definitely the clinical value and determinants of Sokolow-Lyon voltage in patients with IDCM. 
| CONCLUSION
